Penicillin G (Pen G) →supply up
China
China accounts for 82% of Penicillin G supply, so faster Chinese pharma capacity growth should materially raise PenG availability there.
95% confidence
6-Aminopenicillanic Acid (6-APA) →supply up
Antibiotics
6-APA is a critical input to antibiotics, so higher 6-APA availability should raise antibiotic output.
94% confidence
Penicillin G (Pen G) →supply up
Antibiotics
Penicillin G is a critical input into antibiotics, so more PenG supply should increase antibiotics availability.
94% confidence
7-Aminocephalosporanic Acid (7-ACA) →supply up
Antibiotics
7-ACA is a critical input to antibiotics, so more Chinese 7-ACA capacity should lift antibiotic availability.
93% confidence
Salicylic acid (aspirin precursor) →supply up
OTC medicines
Salicylic acid is an input to OTC medicines, so expanding Chinese production capacity should make this precursor more available and ease supply of the finished medicines.
90% confidence
Aspirin (acetylsalicylic acid) API →supply up
China
China already accounts for 82% of this API's supply, and the event explicitly says Chinese pharma capacity will expand, so aspirin API supply from China should rise.
90% confidence
Salicylic acid (aspirin precursor) →supply up
China
China already represents 17.5% of salicylic acid supply, so the headline's China capacity expansion should increase its supply contribution for this input.
88% confidence
7-Aminocephalosporanic Acid (7-ACA) →Stands to benefit
China
China supplies 75% of 7-ACA, so faster Chinese pharma expansion should strengthen the country's dominant source position for this input.
87% confidence
Antidepressants and mental health medications →supply up
Psychiatric Drug Active Pharmaceutical Ingredients
China's pharma capacity expansion directly increases supply of psychiatric APIs used to make antidepressants, so this upstream input becomes more available.
84% confidence
Antidepressants and mental health medications →supply up
Pharmaceutical Key Starting Materials (KSMs)
Rising Chinese pharma production also lifts availability of KSMs that feed API production for antidepressant manufacturing.
82% confidence
OTC medicines →supply up
Acetaminophen (APAP) API
A broad expansion of China's pharma capacity should raise availability of this critical APAP input, which has the strongest dependency on OTC medicines.
82% confidence
Penicillin G (Pen G) →Stands to benefit
North China Pharmaceutical (NCPC)
NCPC is a major Penicillin G supplier with a 20% share, so expanded Chinese capacity is a direct tailwind to its PenG business.
80% confidence
6-Aminopenicillanic Acid (6-APA) →Stands to benefit
China
China supplies 80% of 6-APA, so a China-led pharma capacity expansion should materially benefit the dominant source node.
80% confidence
Penicillin G (Pen G) →Stands to benefit
CSPC Pharmaceutical Group1093.HK
CSPC is another large Penicillin G supplier, and higher Chinese pharmaceutical capacity should support its PenG output and sales.
78% confidence
Aspirin (acetylsalicylic acid) API →supply up
OTC medicines
Aspirin API is a critical input to OTC medicines, so more API supply should raise OTC medicine availability and ease production constraints.
74% confidence
6-Aminopenicillanic Acid (6-APA) →Stands to benefit
North China Pharmaceutical (NCPC)
NCPC already accounts for about 25% of 6-APA supply, so broader capacity growth in China should support output for this major domestic producer.
74% confidence
OTC medicines →supply up
Ibuprofen API
China's pharma buildout should also increase availability of ibuprofen API, another core OTC medicines input.
72% confidence
OTC medicines →supply up
Aspirin (acetylsalicylic acid) API
Broader OTC medicines capacity growth in China should lift supply of aspirin API, a major oral OTC ingredient.
66% confidence
OTC medicines →supply up
Para-aminophenol (PAP) — APAP precursor
If OTC medicines output rises in China, the upstream PAP precursor pool should also improve, though the link is one step more indirect.
65% confidence
Aspirin (acetylsalicylic acid) API →Stands to benefit
Shandong Xinhua Pharmaceutical
As the largest identified supplier with 45% market share, Shandong Xinhua should benefit from a larger Chinese aspirin-API production base and greater output opportunities.
60% confidence
China →Stands to benefit
Summit Therapeutics Inc.SMMT
Summit relies on Akeso in China, so faster growth in China's innovative pharma sector plausibly improves the partner's development/manufacturing capacity and helps Summit's pipeline.
46% confidence
